Presented at the American Public Health Association (APHA) annual meeting, Washington, DC, Oct. 28 - Nov. 2, 2011.
Walter Ling, MD (University of California, Los Angeles, PR Node), Andrew J. Saxon, MD (VA Medical Center, PN Node).
Currently in the United States, pharmacological treatment of opioid addiction most commonly consists of replacement therapy with either methadone or buprenorphine/naloxone (bup/nal). Several clinical trials from the NIDA Clinical Trials Network have demonstrated the effectiveness of bup/nal in a variety of treatment settings and populations. Most recently a multi-site, open label, Phase IV study randomized 1269 participants in federally licensed opioid treatment programs to receive either six months of methadone or six months of bup/nal (CTN-0027, "START"). The primary outcomes of the study focused on parameters of liver function; 731 participants completed the study. Worsening of indices of liver health was rare and did not differ by medication condition. Participants in the bup/nal group had poorer treatment retention than did participants on methadone. Adoption of bup/nal treatment in licensed opioid treatment programs will require additional efforts towards treatment retention. (Presentation, PowerPoint slides, English, 2011)
Keywords: Buprenorphine/Naloxone | Community health services | Liver enzymes | Methadone maintenance | Opioid dependence | Pharmacological therapy | Retention - Research | Suboxone | American Public Health Association (APHA) annual meeting, 2011
Document No: 779.
Submitted by Andrew Saxon, MD, PN Node, 11/21/2011.